Creating a Robust Donor Ecosystem to Accelerate Patient Access to Cell and Gene Therapies
The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of […]